Strategic License Agreement - Additional Information (Details)	1 Months Ended			3 Months Ended	12 Months Ended
	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jan. 31, 2017 USD ($) LicenseAgreement	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) LicenseAgreement € / shares $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized					$ 2,329,000	$ 18,739,000	$ 0
Current deferred revenue					517,000	2,359,000
Contract liabilities					2,696,000	3,576,000	0
Contract assets					$ 0	0	0
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
License and supply agreement date					Mar. 21, 2021
Non refundable payment received				$ 21,500,000
Additional upfront payment to be received				$ 120,800,000
Rate of revenue share				25.00%
Upfront payment				$ 21,500,000
Transaction price	$ 25,100,000
Allocation price net				$ 12,000,000.0
Reimbursement	3,000,000.0
Total deferred revenue					$ 2,700,000	3,600,000
Current deferred revenue					$ 500,000	2,400,000
Estimated amount incurred	$ 3,600,000
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial				50.00%
Costs incurred in performing PIP Trial				$ 1,800,000
Milestone payments exchange rate | € / shares					1.00
Immedica Pharma AB | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments exchange rate | $ / shares					1.07
Immedica Pharma AB | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 12,000,000.0				12,000,000.0	0
Immedica Pharma AB | PEACE Trial and BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price				9,600,000
Revenue recognized					$ 2,300,000	6,700,000
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price				$ 3,500,000
University of Texas at Austin | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date					2013-12
Number of license agreements | LicenseAgreement			1		2
Maximum future contingent license payment			$ 6,400,000
Aggregate potential milestone payments for receipt of regulatory approval			5,000,000.0
Aggregate potential milestone payments for final regulatory approval of second indication			$ 500,000
Milestone payments					$ 100,000
Annual license fees paid						$ 100,000	$ 100,000
University of Texas at Austin | License Agreements | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Rate of revenue share			25.00%
University of Texas at Austin | License Agreements | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Rate of revenue share			6.50%